Literature DB >> 28340881

CD30+ Lymphoproliferative Disorders of the Skin.

Maxwell B Sauder1, John T O'Malley1, Nicole R LeBoeuf2.   

Abstract

Primary cutaneous CD30+ lymphoproliferative disorders encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and indeterminate cases. LyP is a benign disorder characterized by recurrent crops of red or violaceous papulonodules. Patients with LyP are at an increased risk of a secondary malignancy. pcALCL is characterized by a solitary red to violaceous nodule or tumor larger than 20 mm. LyP is benign, is limited to the skin, and self-resolves, with a 5-year survival rate of 100%; pcALCL is limited to the skin and responsive to directed therapies, with a 5-year survival rate of over 95%. Aggressive chemotherapeutic regimens should be avoided.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD30(+); Cutaneous lymphoproliferative disorders; Lymphomatoid papulosis; Primary cutaneous anaplastic large cell lymphoma; Secondary cutaneous anaplastic large cell lymphoma

Mesh:

Year:  2017        PMID: 28340881      PMCID: PMC5776746          DOI: 10.1016/j.hoc.2016.11.006

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  56 in total

Review 1.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Carbamazepine-induced pseudolymphoma with CD-30 positive cells.

Authors:  D L Nathan; D V Belsito
Journal:  J Am Acad Dermatol       Date:  1998-05       Impact factor: 11.527

3.  CD30-positive T-cell-rich pseudolymphoma induced by gold acupuncture.

Authors:  K J Kim; M W Lee; J H Choi; K J Sung; K C Moon; J K Koh
Journal:  Br J Dermatol       Date:  2002-05       Impact factor: 9.302

4.  Carbamazepine-induced lymphadenopathy mimicking Ki-1 (CD30+) T-cell lymphoma.

Authors:  W Yeo; J Chow; N Wong; A T Chan; P J Johnson
Journal:  Pathology       Date:  1997-02       Impact factor: 5.306

Review 5.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Authors:  Werner Kempf; Katrin Pfaltz; Maarten H Vermeer; Antonio Cozzio; Pablo L Ortiz-Romero; Martine Bagot; Elise Olsen; Youn H Kim; Reinhard Dummer; Nicola Pimpinelli; Sean Whittaker; Emmilia Hodak; Lorenzo Cerroni; Emilio Berti; Steve Horwitz; H Miles Prince; Joan Guitart; Teresa Estrach; José A Sanches; Madeleine Duvic; Annamari Ranki; Brigitte Dreno; Sonja Ostheeren-Michaelis; Robert Knobler; Gary Wood; Rein Willemze
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

6.  Regional lymphomatoid papulosis: a report of four cases.

Authors:  J J Scarisbrick; A V Evans; A J Woolford; M M Black; R Russell-Jones
Journal:  Br J Dermatol       Date:  1999-12       Impact factor: 9.302

7.  Gemcitabine-associated CD8+ CD30+ pseudolymphoma.

Authors:  G Marucci; E Sgarbanti; A Maestri; C Calandri; G Collina
Journal:  Br J Dermatol       Date:  2001-10       Impact factor: 9.302

8.  CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.

Authors:  C A Smith; H J Gruss; T Davis; D Anderson; T Farrah; E Baker; G R Sutherland; C I Brannan; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

Review 9.  CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.

Authors:  Geetika Bhatt; Kami Maddocks; Beth Christian
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

10.  Systemic cytokine administration alters the histology of the eruption of lymphocyte recovery.

Authors:  T Horn; M A Lehmkuhle; S Gore; A Hood; P Burke
Journal:  J Cutan Pathol       Date:  1996-06       Impact factor: 1.587

View more
  3 in total

Review 1.  Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.

Authors:  Lauren Shea; Neha Mehta-Shah
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

2.  Angiodestructive lymphomatoid papulosis lasting more than 45 years.

Authors:  Gun Ho Lee; Gordon H Bae; Kerri E Rieger; Youn H Kim; Albert S Chiou
Journal:  JAAD Case Rep       Date:  2019-08-29

3.  Ulcerated nodules in a sporotrichoid distribution.

Authors:  Anna-Marie Hosking; Christina N Kraus; Ashley N Elsensohn; Jessica Shiu; Sebastien de Feraudy; Janellen Smith
Journal:  JAAD Case Rep       Date:  2019-10-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.